This book will be informative and challenging for scientists, enlightening and stimulating for intellectuals and serious students, and highly beneficial and interesting for Alzheimer's workers and the public. The first half is a historical account of recent scientific discoveries on calcium (Ca2+) storage and control organelles in cells, explaining the major role of secretory granules in the cytoplasm and the newly identified nucleoplasmic Ca2+ store vesicles in the nucleus. The second half not only presents unprecedented and highly relevant information on the pathogenic process of Alzheimer's disease and current research, but also introduces Alzheimer's therapeutics, which is ready to proceed to clinical trials. In light of this, it contains valuable information which will greatly benefit Alzheimer's workers, patients, the families, and anybody interested in Alzheimer's disease.
See more
Current price
€87.39
Original price
€91.99
Save 5%
Delivery/Collection within 10-20 working days
Product Details
Dimensions: 148 x 212mm
Publication Date: 29 Apr 2024
Publisher: Cambridge Scholars Publishing
Publication City/Country: United Kingdom
Language: English
ISBN13: 9781036404239
About Seung Hyun Yoo
Seung Hyun Yoo PhD was born in the Republic of Korea and graduated from Seoul National University Seoul Republic of Korea as a zoology major. He has a PhD in Chemistry from the University of Texas Austin USA. He has worked on chromogranin A and the IP3-sensitive Ca2+ store role of secretory granules at the University of Texas Southwestern Medical Center Dallas USA as well as the National Institutes of Health Maryland USA where he continued to work on chromogranins A and B as a principal investigator. Seung Hyun Yoo later returned to Republic of Korea to work at the Korea Advanced Institute of Science and Technology and thereafter at Inha University Medical School in Incheon as biochemistry professor. Here he discovered the IP3-sensitive nucleoplasmic Ca2+ storage and control organelle. After retiring from Inha and starting a biotech startup he identified granin proteins as the pathogenic target of Alzheimer's disease and developed Alzheimer's therapeutics.